Upon detailed characterization of our HNSCC three-dimensional (3D) cell culture and animal models, a reciprocal prosurvival bypass signaling induced by β1 integrin (AIIB2) or EGFR targeting (Cetuximab) led us to a simultaneous targeting of both receptors for radiosensitization [12]. Here, EGFR is linked to head and neck squamous cell carcinoma.